Pfizer’s first-quarter revenue missed analyst estimates as it faces an “uncertain and volatile external environment.” ...

The company expects to save an additional $1.2 billion from automation, AI and other digital tools.

Despite a 6% revenue drop, Pfizer Inc (PFE) focuses on R&D advancements, cost savings, and dividend growth to drive future ...

After years of falling Covid treatment sales, lukewarm drug launches and a fizzled out weight-loss play, Pfizer is focusing on cost-cutting and reinvesting in new drug research in hopes that it can ...

Discover Pfizer's Q1 2025 earnings insights, including strategic R&D updates, financial guidance, and cost-saving initiatives.

Pharma giant now looking for $7.7bn in annual savings by 2027 as it grapples with falling post-Covid sales and lack of new ...

Pfizer’s PFE $13.7 billion in revenue (an 8% decline) and adjusted diluted EPS of $0.92 (12% growth) allowed the firm to maintain its full-year guidance of $61 billion-$64 billion in revenue and $2.80 ...

At Asembia’s AXS25 Summit, industry experts explored how pharmacy is evolving to meet rising patient expectations and ...

Cola, Spotify, Starbucks, and more. From missed profits to tariff tensions, here's what investors need to know about the ...

The drugmaker reported adjusted earnings per share of 92 cents, beating expectations of 67 cents, according to analysts ...

Pfizer stock jumped Tuesday after the S&P 500 drugmaker beat first-quarter profit expectations on the back of savvy ...

The rivalry between Moderna and Pfizer/BioNTech in commercialising their COVID-19 vaccines has now spilled over into the courts, in the form of a patent infringement lawsuit.